Compacted hemostatic cellulosic aggregates
AssigneeCilag GmbH International
InventorYi-Lan Wang
Life of this patent
Estimating the term…
Abstract
The present invention is directed to a hemostatic material comprising a compacted, hemostatic aggregates of cellulosic fibers. In some aspects, the hemostatic material further includes additives, such as carboxymethyl cellulose (CMC) or other polysaccharides, calcium salts, anti-infective agents, hemostasis promoting agents, gelatin, collagen, or combinations thereof. In another aspect, the present invention is directed to a method of making the hemostatic materials described above by compacting a cellulosic-based material into hemostatic aggregates. In another aspect, the present invention is directed to a method of treating a wound by applying hemostatic materials described above onto and/or into the wound of a patient.
Claims7
A method of treating a wound comprising applying a hemostatic flowable plurality of cellulosic aggregates onto and/or into the wound of a patient, wherein said aggregates hemostatic flowable plurality of cellulosic aggregates comprise interconnected individual cellulosic fibrils having a dimension along their longest axis that is less than about 500 microns and greater than about 50 microns;
- wherein said cellulosic aggregates have a size distribution profile with d15 greater than about 80 microns, d50 from about 140 to 250 microns, d90 less than about 370 microns, a bulk density greater than 0.45 g/mL, and sphericity (sh50) equal or greater than 0.7 and substantially no size distribution changes or minimal size distribution changes after subjected to a vibratory challenge.
A method of treating a wound comprising applying a hemostatic flowable plurality of cellulosic aggregates onto and/or into the wound of a patient, wherein said aggregates hemostatic flowable plurality of cellulosic hemostatic aggregates comprise interconnected individual cellulosic fibrils having a dimension along their longest axis that is less than about 500 microns and greater than about 50 microns, wherein said hemostatic aggregates have a size distribution profile with d15 greater than about 80 microns, d50 from about 140 to 250 microns, d90 less than about 370 microns, a bulk density greater than 0.45 g/mL, and sphericity (sh50) equal or greater than 0.7 and a mechanical stability characterized by the aggregates having substantially no size distribution changes or minimal size distribution changes after subjected to processing at 1.0 bar vacuum.
Dependencies are inferred from the claim text.